ANZCTR search results

The primary aim of this prospective cohort study is to audit compliance with perioperative diabetes guidelines for patients undergoing elective surgery in Australia and Aotearoa New Zealand. Secondary aims include exploring associations between concordance with guideline recommendations and incidence of postoperative complications.

This study aims to investigate the effectiveness of graded sensorimotor retraining compared with i) supervised exercise and ii) guideline care for people with chronic low back pain in primary care clinical settings (Physiotherapy and Exercise Physiology clinics). Primary aim: • To determine the effect of graded sensorimotor retraining on the dual primary outcomes disability and pain intensity for adults with chronic non-specific low back pain compared to (i) supervised exercise and (ii) guideline care at 18 weeks post randomization. (Primary effectiveness evaluation) Secondary aim(s) • To determine the effect of graded sensorimotor retraining on secondary outcomes disability (26 and 52 weeks post randomization), pain intensity (26 and 52 weeks post randomization), recovery (18 and 26 weeks post randomization), quality of life, global perceived effect, pain interference, back beliefs, health care and medication use, work related outcomes, adverse events and serious adverse events at 18, 26 and 52 weeks post randomization. (Secondary effectiveness evaluation) • To investigate the cost-effectiveness and cost utility of graded sensorimotor retraining from a societal and health systems perspective. (Economic evaluation) • To investigate the implementation of graded sensorimotor retraining, determining: (i) implementation outcomes (acceptability, appropriateness, fidelity and implementation cost; and (ii) contextual barriers and facilitators to implementation. (Implementation evaluation)

Children often experience significant pain, stress, and fear during medical procedures in emergency departments (EDs). While medicines help, many children still feel distressed. New approaches such as virtual reality (VR) may offer additional support by using headsets to immerse children in interactive games and stories that distract them from painful procedures. VR shows promise but is not yet widely used in paediatric EDs. This project will investigate whether VR is practical, effective, and affordable across three very different Queensland hospitals: Queensland Children’s Hospital (tertiary), Caboolture Hospital (urban), and Kingaroy Hospital (rural). Phase 1 will involve parents, children, nurses, and doctors working with researchers to design how VR should be integrated into routine ED care, select suitable VR content, and develop staff training resources. Phase 2 will test VR in real ED settings through a randomised controlled trial to measure children’s pain and distress, parent satisfaction, staff feedback, and stress hormone levels using simple saliva tests. This project aims to provide clear evidence on how VR can reduce children’s pain and distress in emergency care, ensuring ALL children receive the best support.

This study aims to evaluate the feasibility of a digital stress-mindset intervention for construction workers, with a secondary aim of examining preliminary changes in perceived stress. The intervention adopts a stress-as-enhancing framework, educating participants about stress responses and the role of stress mindsets in reframing stress experiences. Feasibility outcomes will include recruitment, retention, and measure completion, while intervention effectiveness will be assessed using the Perceived Stress Scale at baseline and post-intervention

This open label, safety, acceptability and feasibility trial aims for determine whether two doses of Pomaglumetad methionil (2 X 40mg, 80mg in total) per day over a 12-week period is safe, acceptable and tolerable in young people aged 18-25 years with first-episode psychosis (i.e., the first onset of a psychotic disorder in the lifetime of an individual, FEP) or at clinical high risk for psychosis (i.e., a state in which specific predictive criteria are met which indicate that the person has an increased chance of transitioning to a psychotic illness in the future, CHR). Safety of dose and administration will be determined using safety bloods, side effects profile and treatment-emergent adverse events. Acceptability/tolerability will be assessed using recruitment and retention rates, protocol adherence (including medication adherence), stakeholder acceptability, and time to discontinuation. Secondary/exploratory aims will investigate changes from baseline after 12 weeks of treatment at full study dose in total symptomatology and dysfunction, positive and negative symptoms, quality of life and functioning. Target engagement of the investigational product will be assessed with MRI (optional component).

We propose this trial to test a modified MST and the gold standard BCTT in healthy children aged 8 –18 years . The modified protocol front-loads early increments and slows higher-intensity increments to better match BCTT exertion profiles. The perceived level of exertion and HR measured during the new Modified Shuttle Test (MST) will correlate with those measured during the Buffalo Concussion Treadmill Test (BCTT) in children without concussion.

Eph receptors are proteins found on cells that help guide how cells grow, move, connect, and survive. One of these proteins, called EphA4, is especially important in the brain and spinal cord. It helps guide nerve growth and nerve connections, and it may also affect how nerve cells respond to damage. Research suggests that EphA4 may play a role in how ALS progresses and could be a useful target for treatment. NUN-004 is an investigational medicinal product consisting of a modified EphA4 receptor. NUN-004 is taken via IV infusion. The study will include 75 people with ALS across several study sites. Participants will be randomly assigned to receive either NUN-004 or a placebo for up to 24 weeks. After the first 24 weeks, participants may continue into an open-label extension for another 24 weeks. In this extension, all participants will receive NUN-004. The main goal of the study is to see whether NUN-004 can slow the progression of ALS. This will be measured using a standard ALS rating scale. The study will also be assessing safety and tolerability of NUN-004.

People with angina and non-obstructive coronary arteries (ANOCA) often continue to experience chest pain despite standard medical treatment. This study will investigate whether a non-invasive ear stimulation device that activates the vagus nerve can improve angina symptoms in people with ANOCA. Participants will use the device at home for 60 minutes each day for four weeks while continuing their usual medical care. The study will assess changes in angina symptoms, quality of life, heart rate variability, treatment adherence, and device safety. The findings will help determine whether this treatment is feasible, safe, and potentially effective, and whether a larger randomised clinical trial should be undertaken.

Diets rich in plant foods such as whole grains, legumes, nuts, seeds, fruits, and vegetables are associated with a lower risk of type 2 diabetes and may improve blood sugar control and overall heart and metabolic health. In contrast, diets high in ultra-processed foods (manufactured products that often contain ingredients extracted from foods combined with additives, flavourings, and preservatives) such as hotdogs and deli meats may increase the risk of type 2 diabetes. Many people following a plant-based diet also consume plant-based ultra-processed foods (e.g. chips/crisps, plant-based burgers, cereals, chocolate). However, it is not yet clear how these foods affect diabetes risk and metabolic health. The purpose of this study is to examine how a vegan diet high in plant-based ultra-processed foods affects insulin sensitivity, blood sugar control, and other markers of cardiometabolic health. The findings will help improve our understanding of how different types of plant-based foods may influence risk factors for type 2 diabetes.

Brief description of study purpose: CLARITY is a research study investigating how interferon (IFN) alpha, a treatment commonly used for myeloproliferative neoplasms (MPNs), affects blood cancer cells over time. By studying blood and bone marrow samples collected before and during treatment, researchers hope to better understand why some patients respond differently to IFN alpha and identify biological markers that may help improve future treatment and monitoring of MPNs. Who is it for? This study is for adults aged 18 years and older with a confirmed diagnosis of a myeloproliferative neoplasm (MPN) who are planning to start IFN alpha treatment as part of their usual care. Participants with a JAK2V617F-positive MPN and additional high-risk clinical or genetic features may be eligible for the study's monitoring cohort. Study details: CLARITY is being conducted at hospitals across Australia. Researchers plan to screen at least 125 people, with up to 62 participants joining the monitoring cohort, which includes additional study-specific blood and bone marrow sample collection. Participants will be followed for up to two years. CLARITY does not test a new treatment. All participants will receive IFN alpha as prescribed by their treating doctor, and all treatment decisions will remain part of routine clinical care. Participants in the monitoring cohort will provide blood and bone marrow samples before starting IFN alpha treatment and again during treatment. Researchers will analyse these samples to study genetic and biological changes in MPN cells over time and compare these findings with information collected from routine medical care. The information gained from this study may help researchers develop better ways to monitor MPNs, understand which patients are most likely to benefit from IFN alpha treatment, and improve future treatment strategies for people living with MPNs.